A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis by Henry, A, Kyle, S, Chisholm, A, Griffiths, C, Bundy, C

“…BACKGROUND: Research suggests that sleep disturbance is common in psoriasis. While several sleep investigations have been conducted in psoriasis populations, many have methodological shortcomings, and no study has examined multiple dimensions of sleep-wake functioning. …”

Disease severity in Ankylosing Spondylitis: The influence of associated inflammatory bowel disease and psoriasis by Bradbury, L, Lewington, M, Warner, J, Farrar, C, Wordsworth, B, Brown, M

Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. by Chen, H, Hayashi, G, Lai, O, Dilthey, A, Kuebler, P, Wong, T, Martin, M, Vina, F, McVean, G, Wabl, M, Leslie, K, Maurer, T, Martin, J, Deeks, S, Carrington, M, Bowcock, A, Nixon, D, Liao, W

“…We analyzed the HLA class I and class II alleles of 1,727 Caucasian psoriasis cases and 3,581 controls and found that psoriasis patients are significantly more likely than controls to have gene variants that are protective against HIV-1 disease. …”

A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis. by Foulkes, AC, Watson, DS, Carr, DF, Kenny, JG, Slidel, T, Parslew, R, Pirmohamed, M, PSORT Consortium, Anders, S, Reynolds, NJ, Griffiths, CEM, Warren, RB, Barnes, MR

“…Biologic therapies have shown high efficacy in psoriasis, but individual response varies and is poorly understood. …”

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity by Tsoi, L, Tsoi, L, Spain, S, Spain, S, Knight, J, Knight, J, Knight, J, Ellinghaus, E, Ellinghaus, E, Stuart, P, Capon, F, Ding, J, Li, Y, Tejasvi, T, Gudjonsson, J, Kang, H, Allen, M, McManus, R, McManus, R, Novelli, G, Novelli, G, Samuelsson, L, Schalkwijk, J, Ståhle, M, Burden, A

“…To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. …”

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation by Coates, L, Murphy, R, Helliwell, P

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial by William Tillett, Alexander Egeberg, Enikö Sonkoly, Patricia Gorecki, Anna Tjärnlund, Jozefien Buyze, Sven Wegner, Dennis McGonagle

Subjects: “…Nail psoriasis…”
Get full text

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes by Luís Puig, Martin Dossenbach, Lovisa Berggren, Anders Ljungberg, Claus Zachariae

Subjects: Get full text

Psoriasis: aspectos comparativos entre la edad pediátrica y adulta de interés para el médico general by Hernan Dante Moumdjian, DR, Delia Ibañez Gómez

Subjects: “…Psoriasis; Terapéutica…”
Get full text

Decreased epidermal AXL expression and increased infiltration of AXL‐expressing dendritic cells in psoriasis by Yukiko Ito, Sayaka Shibata, Asumi Koyama, Lixin Li, Eiki Sugimoto, Haruka Taira, Yuka Mizuno, Kentaro Awaji, Shinichi Sato

Subjects: Get full text

Lycopene Inhibit IMQ-Induced Psoriasis-Like Inflammation by Inhibiting ICAM-1 Production in Mice by Chun-Ming Shih, Chi-Kun Hsieh, Chien-Yu Huang, Chun-Yao Huang, Kuo-Hsien Wang, Tsorng-Harn Fong, Nguyen Thi Thu Trang, Kuan-Ting Liu, Ai-Wei Lee

Subjects: Get full text

New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab by O. V. Zhukova, E. I. Kasikhina, M. N. Ostretsova, N. N. Potekaev

Subjects: “…psoriasis…”
Get full text

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: a Narrative Review by Maria Vittoria Cannizzaro, Giulia Coscarella, Andrea Chiricozzi

Subjects: Get full text

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3 by Lajos Kemény, Lovisa Berggren, Martin Dossenbach, Yves Dutronc, Carle Paul

Subjects: Get full text

Diffuse rash with silvery scales and anasarca by Cynthia Zheng, MD, Constance Fiocco, MD, Ibiyonu Lawrence, MD

Subjects: Get full text

Mild-to-moderate severity of psoriasis may be assessed remotely based on photographs and self-reported extent of skin involvementCapsule Summary by Zarqa Ali, MD, PhD, John Robert Zibert, MSc, PhD, Priyanka Dahiya, MSc, Cæcilie Bachdal Johansen, MD, Jesper Grønlund Holm, MD, PhD, Astrid-Helene Ravn Jørgensen, MD, Ionela Manole, MD, Alina Suru, MD, Alexander Egeberg, MD, PhD, DMSc, Simon Francis Thomsen, MD, PhD, DMSc, Anders Daniel Andersen, MSc, PhD

Subjects: Get full text

Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis by Neil J. Korman, Howard Sofen, Scott Fretzin, Phoebe Rich, Yang Zhao, Vivian Herrera, Judit Nyirady, Nicole Williams, Margaret Mordin, Stephen Tyring

Subjects: “…psoriasis…”
Get full text

Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest by Kristian Reich, Ulrich Mrowietz, Christina Sorbe, Ralph von Kiedrowski, Sebastian Diemert, Lisa Schaeffer, Natalia Kirsten, Nesrine Ben-Anaya, Matthias Augustin

“…Objectives Fumaric acid esters (FAEs) are a well-established treatment option for long-term therapy of moderate to severe plaque psoriasis. This study examines effectiveness of FAEs for the treatment of plaque psoriasis in real-world practice at 12 months and if patient characteristics affect the odds of clinical response. …”
Get full text

Variation at ACOT12 and CT62 locus represents susceptibility to psoriasis in Han population by Jianxiao Xing, Xincheng Zhao, Xiaofang Li, Ying Wang, Junqin Li, Ruixia Hou, Xuping Niu, Guohua Yin, Xinhua Li, Kaiming Zhang

Subjects: Get full text

TOLL-LIKE RECEPTOR 7 GENE Gln11Leu MISSENSEMUTATION AND SUSCEPTIBILITY TO PSORIASIS by E. S. Galimova, K. Kingo, S. Koks

Subjects: “…psoriasis…”
Get full text